logo BDSP

Base documentaire


  1. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children.

    Article - En anglais

    Inhaled corticosteroids form the mainstay of the treatment and management of asthma and the results of a meta-analysis comparing two of the most frequently prescribed inhaled corticosteroids, fluticasone propionate and budesonide, administered in a clinically equivalent 1 : 2 dose ratio to 1980 patients with asthma, demonstrated that fluticasone propionate had an improved efficacy : safety ratio.

    However, limited data are available on the relative economic benefits of fluticasone propionate and budesonide.

    The database for clinically relevant parameters, for which the efficacy : safety meta-analysis had demonstrated statistical significance between the two corticosteroids, was used for this pharmacoeconomic analysis.

    Treatment with fluticasone propionate was more cost-effective than budesonide with respect to improvement in morning peak expiratory flow rate, successfully treated weeks, symptom-free days, symptom-free 24 h and episode-free days.

    The costs of treatment for fluticasone propionate and budesonide were £7.78 per week and £12.33 per week, respectively.

    The main contributing factor to the higher costs of budesonide was the higher cost of health care contacts, which were £4.53 per week for budesonide and £0.57 per week for fluticasone propionate.

    The pharmacoeconomic difference increased in favour of fluticasone propionate as the criteria for success were made more stringent. (...)

    Mots-clés Pascal : Asthme, Chimiothérapie, Traitement, Budésonide, Efficacité traitement, Etude comparative, Fluticasone, Coût, Economie santé, Enfant, Homme, Adulte, Corticostéroïde, Appareil respiratoire pathologie, Bronchopneumopathie obstructive, Antiasthmatique, Antiinflammatoire

    Mots-clés Pascal anglais : Asthma, Chemotherapy, Treatment, Budesonide, Treatment efficiency, Comparative study, Fluticasone, Costs, Health economy, Child, Human, Adult, Corticosteroid, Respiratory disease, Obstructive pulmonary disease, Antiasthma agent, Antiinflammatory agent

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0380056

    Code Inist : 002B02D. Création : 22/03/2000.